Abbott Laboratories (ABT) Projected to Post Earnings on Wednesday

Key Points

• Abbott Laboratories is expected to announce its Q3 2025 earnings on October 15th, forecasting earnings of $1.30 per share and revenue of $11.4 billion for the quarter.
• The company has declared a quarterly dividend of $0.59, which will be paid on November 17th, with an annualized yield of 1.8%.
• Abbott Laboratories' stock is currently rated as a "Moderate Buy" with an average target price of $146.24 from various analysts.

Abbott Laboratories (NYSE:ABT - Get Free Report) is anticipated to release its Q3 2025 results before the market opens on Wednesday, October 15th. Analysts expect Abbott Laboratories to post earnings of $1.30 per share and revenue of $11.4004 billion for the quarter. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS.Interested persons may review the information on the company's upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, October 15, 2025 at 9:00 AM ET.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.01 billion. During the same period last year, the firm posted $1.14 earnings per share. The business's revenue for the quarter was up 7.4% on a year-over-year basis. On average, analysts expect Abbott Laboratories to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Abbott Laboratories Stock Down 0.5%

ABT stock opened at $133.05 on Wednesday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The stock has a market cap of $231.58 billion, a P/E ratio of 16.67, a PEG ratio of 2.54 and a beta of 0.69. The business's 50-day moving average price is $132.19 and its 200-day moving average price is $131.45.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's payout ratio is currently 29.57%.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Abbott Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in ABT. Riggs Asset Managment Co. Inc. boosted its stake in Abbott Laboratories by 9.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker's stock worth $140,000 after buying an additional 88 shares during the last quarter. McIlrath & Eck LLC lifted its stake in Abbott Laboratories by 16.0% during the 2nd quarter. McIlrath & Eck LLC now owns 1,122 shares of the healthcare product maker's stock worth $153,000 after acquiring an additional 155 shares in the last quarter. Kestra Investment Management LLC lifted its stake in Abbott Laboratories by 27.8% during the 2nd quarter. Kestra Investment Management LLC now owns 2,269 shares of the healthcare product maker's stock worth $309,000 after acquiring an additional 494 shares in the last quarter. Florida Financial Advisors LLC lifted its stake in Abbott Laboratories by 10.8% during the 2nd quarter. Florida Financial Advisors LLC now owns 2,904 shares of the healthcare product maker's stock worth $395,000 after acquiring an additional 282 shares in the last quarter. Finally, Ruggaard & Associates LLC lifted its stake in Abbott Laboratories by 19.8% during the 2nd quarter. Ruggaard & Associates LLC now owns 3,634 shares of the healthcare product maker's stock worth $494,000 after acquiring an additional 601 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

ABT has been the topic of a number of research reports. Raymond James Financial reduced their price objective on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research note on Friday, July 18th. Royal Bank Of Canada boosted their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research report on Tuesday, July 15th. Mizuho boosted their target price on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Finally, The Goldman Sachs Group upped their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the company a "buy" rating in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, Abbott Laboratories currently has an average rating of "Moderate Buy" and an average target price of $146.24.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.